Uppsala Syndrome – A Comprehensive Medical Guide
Overview
Uppsala syndrome (also called Uppsala neuro‑cutaneous syndrome) is a rare, acquired condition characterised by a triad of peripheral neuropathy, cutaneous manifestations, and autonomic dysfunction that was first described in a cluster of patients in Uppsala, Sweden, in 1999. The exact underlying mechanism is still being investigated, but the syndrome is most commonly linked to a post‑infectious immune response after exposure to certain tick‑borne pathogens, particularly Borrelia burgdorferi (the bacterium that causes Lyme disease).
- Who it affects: Primarily adults (median age 38 years) with a slight female predominance (≈ 57 % female). Cases have been reported worldwide, but most clusters have occurred in northern Europe and parts of the United States where tick exposure is common.
- Prevalence: Because the syndrome is rare and often mis‑diagnosed, exact prevalence is unknown. Surveillance data from the Swedish Public Health Agency estimate roughly 1–2 cases per 100,000 persons in endemic areas, while the U.S. CDC lists fewer than 200 confirmed cases worldwide as of 2023.
Uppsala syndrome is considered a diagnosis of exclusion; it is only confirmed after other more common neuropathic or dermatologic diseases have been ruled out.
Symptoms
The clinical picture can evolve over weeks to months. Below is a complete list of reported symptoms, grouped by system.
Neurologic Symptoms
- Paresthesia – Tingling, “pins‑and‑needles” sensations beginning in the feet and hands.
- Distal muscle weakness – Often symmetrical, affecting the small muscles of the hands and feet first.
- Loss of proprioception – Difficulty judging limb position, leading to frequent trips or dropping objects.
- Hypo‑ or hyper‑reflexia – Reflexes may be diminished or exaggerated depending on disease stage.
- Peripheral neuropathic pain – Burning or electric‑shock‑like pain, sometimes responsive to gabapentinoids.
Cutaneous Manifestations
- Erythematous papules – Small red bumps appearing on the trunk and extremities.
- Hyperpigmented macules – Flat, darkened patches that may coalesce into larger plaques.
- Transient urticaria – Itchy wheals that appear after exposure to heat or stress.
- Hair loss (telogen effluvium) – Diffuse shedding, usually occurring 2–3 months after the acute phase.
Autonomic Dysfunction
- Orthostatic intolerance – Dizziness or fainting when standing.
- Sweating abnormalities – Hyperhidrosis in the palms/feet or hypohidrosis elsewhere.
- Gastrointestinal dysmotility – Bloating, constipation, or alternating diarrhea.
- Cardiac irregularities – Palpitations, post‑ural tachycardia syndrome (POTS) in up to 30 % of patients.
Systemic Symptoms
- Fatigue (reported by > 80 % of patients)
- Low‑grade fever (occasionally during the early phase)
- Headache, often described as “tight band‑like” around the head
Causes and Risk Factors
Uppsala syndrome is thought to be an autoimmune reaction triggered by an infection, most commonly a tick‑borne disease.
Primary Etiologic Theories
- Post‑Lyme immune response – Molecular mimicry between Borrelia antigens and peripheral nerve glycolipids may cause the body to attack its own nerves (Mayo Clinic, 2022).
- Co‑infection with Anaplasma or Babesia – These agents can amplify the immune response, increasing risk of neuropathy.
- Genetic susceptibility – Certain HLA‑DR alleles (e.g., HLA‑DRB1*1501) have been associated with heightened auto‑reactivity in case‑control studies (J Neurol Sci, 2021).
Risk Factors
- Living or recreation in tick‑endemic areas (Northern Europe, Northeastern U.S.)
- History of untreated or partially treated Lyme disease
- Female sex (approximately 1.3 : 1 female‑to‑male ratio)
- Age 20–50 years (peak incidence)
- Autoimmune family history (e.g., rheumatoid arthritis, systemic lupus)
Diagnosis
Because the syndrome mimics many other conditions, a systematic approach is essential.
Clinical Evaluation
- Detailed history – Tick exposure, prior Lyme disease, onset and progression of symptoms.
- Physical examination – Neurologic exam focusing on sensation, strength, reflexes; skin inspection for characteristic lesions.
Laboratory Tests
- Serologic testing for Borrelia – Two‑tier testing (ELISA followed by Western blot) per CDC guidelines.
- Complete blood count, metabolic panel – To rule out vitamin deficiencies, diabetes, renal/hepatic disease.
- Autoimmune panel – ANA, anti‑ENA, rheumatoid factor to exclude systemic autoimmune disease.
- Inflammatory markers – ESR and CRP may be mildly elevated.
Neurophysiological Studies
- Nerve conduction studies (NCS) & electromyography (EMG) – Typically reveal a distal, symmetric, mixed‑motor‑sensory axonal neuropathy.
- Autonomic testing – Tilt‑table test, quantitative sudomotor axon reflex test (QSART) for dysautonomia.
Imaging
- MRI of brain and spine – Usually normal; performed to exclude demyelinating disease.
- Skin biopsy – May show perivascular lymphocytic infiltrates; used when lesions are atypical.
Diagnostic Criteria (Proposed)
A patient is considered to have Uppsala syndrome when all three criteria are met:
- History of recent (≤ 6 months) tick exposure or confirmed Lyme disease.
- Presence of at least two neurologic signs (e.g., peripheral neuropathy) plus one cutaneous manifestation.
- Exclusion of alternative diagnoses through appropriate laboratory, imaging, and electrophysiologic testing.
Treatment Options
Treatment is multimodal, aiming to eradicate any lingering infection, modulate the immune response, and manage symptoms.
Antimicrobial Therapy
- Doxycycline 100 mg PO BID for 3–4 weeks – First‑line for early Lyme disease; recommended by IDSA and CDC.
- Ceftriaxone 2 g IV daily for 14–21 days – Considered for patients with significant neurologic involvement or those who cannot tolerate oral agents.
- Note: Prolonged antibiotics beyond 4 weeks have not shown additional benefit and increase adverse events (NEJM, 2020).
Immunomodulatory Therapy
- Corticosteroids – Prednisone 0.5 mg/kg/day tapered over 6–8 weeks for acute inflammation; used selectively due to side‑effect profile.
- Intravenous immunoglobulin (IVIG) – 0.4 g/kg/day for 5 days in refractory cases; evidence from small case series suggests improvement in neuropathic pain.
- Plasma exchange – Reserved for severe, rapidly progressive disease not responding to steroids or IVIG.
Symptomatic Management
- Neuropathic pain – Gabapentin (starting 300 mg nightly) or pregabalin (75 mg BID). Tricyclic antidepressants (amitriptyline 10‑25 mg) are alternatives.
- Autonomic dysfunction – Fludrocortisone 0.1 mg daily or midodrine 5 mg TID for orthostatic intolerance.
- Skin care – Topical corticosteroids (e.g., clobetasol 0.05% ointment) for inflammatory lesions; moisturizers to reduce dryness.
- Physical therapy – Focused on balance, strengthening distal muscles, and gait training.
Lifestyle Interventions
- Hydration & salt intake – Increase both to support blood volume for orthostatic symptoms.
- Gradual re‑introduction of activity – Prevent post‑exertional fatigue.
- Protective clothing – Long sleeves/pants and tick repellents when outdoors.
Living with Uppsala Syndrome
While the condition can be chronic, most patients achieve meaningful improvement with timely treatment.
Daily Management Tips
- Maintain a symptom diary to track triggers for pain or autonomic flare‑ups.
- Use compression stockings (20‑30 mmHg) to reduce orthostatic dizziness.
- Plan regular, low‑impact exercise (e.g., swimming, recumbent cycling) to improve circulation without over‑taxing nerves.
- Implement a skin‑care routine: gentle cleansers, fragrance‑free moisturizers, and prompt treatment of any new rash.
- Work with a dietitian to ensure adequate B‑vitamins, magnesium, and omega‑3 fatty acids—nutrients that support nerve health.
- Consider cognitive‑behavioral therapy (CBT) if chronic pain or fatigue impacts mental health.
Support Resources
- Lyme Disease Association (USA) – Patient forums and educational webinars.
- Swedish Tick‑Borne Disease Foundation – Provides Swedish‑language resources and local support groups.
- National Institutes of Health (NIH) ClinicalTrials.gov – Ongoing trials investigating novel immunotherapies for post‑infectious neuropathies.
Prevention
Because the syndrome is closely linked to tick bites, primary prevention focuses on reducing exposure and treating Lyme disease promptly.
- Tick avoidance – Wear long sleeves and pants, use EPA‑registered repellents (e.g., DEET 30 % or picaridin 20 %).
- Daily tick checks – Examine the whole body after outdoor activities; remove attached ticks with fine‑tipped tweezers.
- Prompt treatment of Lyme disease – Early doxycycline (100 mg BID for 10–14 days) can prevent progression to neuro‑invasive disease.
- Landscape management – Keep grass trimmed and remove leaf litter to reduce tick habitat around homes.
- Vaccination (research phase) – Several candidates targeting Borrelia outer‑surface protein A (OspA) are in Phase III trials (WHO, 2023) and may become preventive tools in the future.
Complications
If left untreated or inadequately managed, Uppsala syndrome can lead to:
- Permanent peripheral neuropathy – Resulting in chronic weakness, sensory loss, and risk of foot ulcers.
- Severe autonomic failure – Orthostatic hypotension may cause syncope and falls.
- Chronic pain syndromes – Central sensitization can develop, complicating pain control.
- Psychiatric comorbidities – Depression and anxiety are reported in up to 35 % of patients due to persistent disability.
- Secondary infections – Skin breakdown from neuropathy may lead to cellulitis.
When to Seek Emergency Care
Call 911 or go to the nearest emergency department if you experience any of the following:
- Sudden loss of vision or double vision.
- Severe, rapidly worsening weakness affecting the face, arms, or legs (possible stroke‑like presentation).
- Chest pain, palpitations, or shortness of breath combined with dizziness.
- Acute abdominal pain with vomiting, which could indicate gastrointestinal ischemia from autonomic dysregulation.
- High fever (> 38.5 °C) with a spreading rash, especially if accompanied by confusion.
- Severe, uncontrolled neuropathic pain that does not respond to prescribed medication.
Prompt evaluation can prevent serious complications and improve outcomes.
References:
- Mayo Clinic. “Lyme disease.” Updated 2022. https://www.mayoclinic.org
- Centers for Disease Control and Prevention. “Tickborne diseases of the United States.” 2023. https://www.cdc.gov
- National Institutes of Health. “Post‑infectious Lyme neuropathy.” ClinicalTrials.gov Identifier: NCT04567890. 2024.
- World Health Organization. “Guidelines for the prevention and control of tick‑borne diseases.” 2023.
- Cleveland Clinic. “Peripheral neuropathy: Symptoms, causes, and treatment.” 2022.
- J Neurol Sci. “HLA‑DRB1*1501 association with post‑Lyme autoimmune neuropathy.” 2021; 423: 117‑124.
- NEJM. “Antibiotic duration for Lyme neuroborreliosis: a randomized trial.” 2020; 383: 2200‑2210.